focus -WSS

focus

author：comprehensive 2025-10-01 21:34:06 - browse：733

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Ransomware attacks on hospitals: Study outlines patient impact

WSS

Surge of respiratory disease in China has likely explanation

What don’t we know about an Alzheimer’s drug side effect?

Cigna, Humana reportedly in talks to merge

Poor hospice wound care hurts patients and families

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

FDA's Woodcock to retire early next year

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The cancer drug shortage isn’t new — and neither are the solutions

Pediatric cancer treatments threatened by a new FDA policy

Medical records are filled with copy

Anthos stroke drug appears safer than common blood thinner

Malaria cases in Florida and Texas: Here’s what you need to know

As biotech industry slumps, bioscience job market is upside down

Cancer drug shortages should be causing more outrage

FDA's Woodcock to retire early next year

knowledge

With clinical trial data readouts, here's how to spot spin

Diagnostic tests are hitting their mathematical limits

What to do when lifesaving products contribute to climate change

Does good food count as health care? Study aims to find out

Congress must reauthorize a committee to support older Americans

Astellas still sees hope in its gene therapy after four deaths

entertainment

leisure time

focus

knowledge